Table 2 Acute treatment experiences of the participants
From: Real-life experiences with galcanezumab and predictors for treatment response in Turkey
Medication classes | %, (n) |
|---|---|
NSAIDs | 55,5 (264) |
Triptans | 66.8% (318) |
Paracetamol | 23,5 (112) |
Combination medications | 23,3 (111) |
Ergotamine | 13.2% (63) |
Metamizole | 0.4% (2) |
Tramadol | 0.4% (2) |